India Next-Generation Cancer Therapeutics Market Size, Share, Growth, and Industry Analysis, By Therapy Type (Targeted Therapy (Small Molecule Inhibitors), Immunotherapy Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) CAR-T Cell Therapy Cancer Vaccines, Gene Therapy, Cell Therapy (e.g., TILs, NK cells) ), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers (Leukemia, Lymphoma, Myeloma) ) and Forecast, 2026-2034

India Next-Generation Cancer Therapeutics Market Trends

Precision Oncology, Indigenous Cell Therapy and Combination Treatment Adoption

Precision oncology is moving treatment selection from organ-based protocols toward molecular targets, biomarkers and patient-specific immune interventions. India's indigenous NexCAR19 program demonstrates this transition: its registration was supported by 2 clinical studies involving 64 patients, while evaluable trial data showed a 67% objective response rate among 53 patients and complete responses in approximately 50%.

Cell engineering, localized manufacturing and combination regimens are increasingly important technology directions. NexCAR19 has been reported at roughly one-tenth the cost of comparable commercial CAR-T products, with production approaches designed to reduce vector and manufacturing expenses. India's cancer burden has simultaneously increased from approximately 980,000 new diagnoses in 2010 to nearly 1.6 million in 2023, supporting demand for scalable targeted, immune and cell-based interventions.

India Next-Generation Cancer Therapeutics Market Drivers

Rising Cancer Burden and Expansion of Precision Treatment Infrastructure

India's growing oncology burden is accelerating investment in molecular diagnostics, targeted drugs and advanced immunotherapy. Nearly 1.6 million new cancer diagnoses were estimated for 2023 compared with approximately 980,000 in 2010, an increase exceeding 60%, while annual cancer deaths were estimated near 800,000. In Karnataka alone, oncology procedure approvals under AB-ArK increased from 9,328 in 2018–19 to 60,301 in 2024–25, with medical oncology accounting for 56% of procedures, demonstrating expanding treatment utilization.

India Next-Generation Cancer Therapeutics Market Restraints

High Treatment Costs and Uneven Access to Advanced Oncology Infrastructure

Affordability remains a constraint because engineered cell therapies require specialized laboratories, trained teams and hospitalization capacity. Commercial CAR-T treatments internationally have been reported at approximately USD 370,000–530,000, whereas India's indigenous alternative costs around one-tenth of comparable products. Even with this reduction, advanced therapies remain expensive relative to conventional treatment, while India's approximately 1.6 million annual diagnoses create substantial pressure on specialist capacity and reimbursement systems.

India Next-Generation Cancer Therapeutics Market Opportunities

Domestic Cell and Gene Therapy Manufacturing Creates an Affordability Opportunity

Indigenous development provides an opportunity to reduce imported-therapy dependence and broaden advanced treatment access. NexCAR19 became India's first approved CAR-T treatment in October 2023 and was formally launched as the country's first home-grown anti-cancer CAR-T therapy in April 2024. Its supporting trials included 64 patients, with a 67% objective response among 53 evaluable patients, establishing a foundation for domestic cell-therapy manufacturing, hospital partnerships and future expansion into additional hematologic indications.

Challenges in India Next-Generation Cancer Therapeutics Market

Clinical Complexity, Manufacturing Scalability and Patient Selection

Scaling individualized therapeutics requires reliable biomarker testing, controlled manufacturing and management of potentially serious immune toxicities. India's first CAR-T approval relied on 2 relatively small studies totaling 64 patients, illustrating the evidence-generation challenge associated with advanced personalized therapies. Meanwhile, the country faces close to 1.6 million new cancer diagnoses annually and approximately 800,000 deaths, creating a substantial mismatch between national treatment requirements and the limited number of facilities capable of delivering complex cell and gene therapies.

India Next-Generation Cancer Therapeutics Market Segmentation

The market is segmented across 6 therapy types, 7 cancer indications, 2 principal modality classes, 4 administration routes, 5 mechanism categories and 4 end-user groups. Targeted therapy leads the quantified therapy segmentation with approximately 38.35% of 2026 revenue, while lung cancer contributes approximately 27.94% of the cancer-type total.

By Therapy Type

Targeted therapy is the largest therapy segment, increasing from USD 2,655.30 million in 2025 to USD 2,873.30 million in 2026 and USD 5,401.57 million by 2034, at an 8.21% CAGR. It contributes approximately 39.54% of the therapy-based 2034 total.

Targeted therapy is also the fastest-growing supplied therapy category at 8.21% CAGR. Immunotherapy follows at USD 1,653.77 million in 2026 and a 7.46% CAGR, while ADCs record 7.76%, RNA-based therapy 7.71%, gene therapy 7.51%, and cell therapy 7.45%.

By Cancer Type

Lung cancer leads in 2026 at USD 2,091.10 million, approximately 27.94% of the cancer-type total, and is projected to reach USD 3,712.82 million by 2034 at a 7.44% CAGR. Breast cancer follows closely at USD 2,039.69 million in 2026.

Pan-tumor therapy is the fastest-growing cancer indication at 7.98% CAGR, compared with breast cancer at 7.96% and brain cancer at 7.83%. Breast cancer reaches USD 3,764.15 million by 2034, making it the largest supplied cancer indication at the forecast endpoint.

By Modality

The modality framework comprises 2 primary categories—monotherapy and combination therapy—with combination approaches further covering 3 specified pairings: immunotherapy plus targeted drugs, chemotherapy plus ADCs, and mRNA plus checkpoint inhibitors. Quantified modality revenue and CAGR were not supplied; therefore, no unsupported market values are assigned.

The increasing clinical emphasis on combinations reflects the need to attack multiple tumor pathways and resistance mechanisms. The segmentation incorporates 3 combination classes against 1 monotherapy class, but percentage dominance cannot be calculated from the mandatory numerical dataset.

By Route of Administration

Administration is divided into 4 routes: intravenous, oral, intratumoral/localized and subcutaneous delivery. These routes correspond to different therapy architectures, ranging from infused antibodies and engineered cells to orally administered small molecules.

No route-specific revenue or CAGR figures were provided in the mandatory tables. Consequently, the 4-route segmentation is maintained qualitatively without fabricating percentage contributions or forecast values.

By Mechanism of Action

The framework covers 5 mechanisms, including checkpoint-mediated immune activation, oncogene targeting, DNA-damage-response modulation, tumor-microenvironment modulation and apoptosis induction. Oncogene targeting includes molecular pathways such as EGFR, KRAS and BRAF.

The 5-category mechanism structure illustrates increasing therapeutic diversification, but mechanism-specific revenue, percentage contribution and CAGR were not included in the supplied numerical dataset and are therefore not estimated.

By End-User

End-users comprise 4 groups: specialized cancer hospitals, academic and research institutes, ambulatory infusion centers and homecare settings. Complex cell therapies remain associated with specialist facilities, whereas oral and selected subcutaneous products can support decentralized treatment.

No end-user market values or CAGR figures were supplied. Accordingly, the 4 end-user categories are assessed structurally rather than assigned unsupported numerical market shares.

India Next-Generation Cancer Therapeutics Market Counties Outlook

India constitutes 100% of the geographic scope of this report. The mandatory dataset provides a national 2026 therapy-based value of USD 7,492.70 million and a 2034 value of USD 13,661.28 million, representing a 7.68% CAGR. No North, South, East, West, state-level or city-level revenue allocation was supplied, so regional percentage shares are not fabricated.

At the national level, targeted therapy contributes approximately 38.35% of the 2026 therapy total, compared with 22.07% for immunotherapy and 15.83% for gene therapy. India's advanced-therapy infrastructure is developing around major oncology and research institutions; NexCAR19 emerged from collaboration involving IIT Bombay and Tata Memorial Centre and became India's first approved indigenous CAR-T therapy.

Top players in India's next-generation cancer therapeutics market

1. F. Hoffmann-La Roche Ltd.
2. AstraZeneca plc
3. Merck & Co., Inc.
4. Bristol Myers Squibb
5. Novartis AG
6. Biocon Limited
7. Dr. Reddy's Laboratories Ltd.
8. Sun Pharmaceutical Industries Ltd.
9. Cipla Limited
10. Zydus Lifesciences Limited
11. Natco Pharma Limited
12. ImmunoACT
13. Glenmark Pharmaceuticals Ltd.
14. Alkem Laboratories Ltd.
15. Lupin Limited

Top Two Companies

• F. Hoffmann-La Roche Ltd.— Company-level percentage share isnot disclosed in the supplied mandatory dataset, so assigning an artificial share would conflict with the numerical requirements. Roche is positioned across targeted oncology and antibody-based treatment categories and participates in an Indian oncology environment serving more than1.4 million new annual cancer cases. Its relevance is reinforced by the market's shift toward biomarker-directed treatment and combinations. The supplied market framework contains6 therapy categoriesand7 cancer indications, providing multiple areas for established oncology portfolios.
• AstraZeneca plc— A defensible company-level% market share cannot be calculatedfrom the supplied tables because they contain therapy- and cancer-level values rather than company revenues. AstraZeneca is nevertheless identified among key oncology participants in India and is positioned around precision and targeted oncology. The addressable environment includes more than1.41 million new cancer cases recorded in 2022, while lung cancer represented8.5%of new male cancer cases according to IARC estimates reported for India.

Recent Developments in India's Next-Generation Cancer Therapeutics Market

• 2026: India's indigenous NexCAR19 continued to represent a domestic advanced cell-therapy milestone, following its regulatory and commercialization pathway for hematologic cancers.
• 2025: Precision and personalized oncology remained a prominent industry direction as targeted treatment and biomarker-led care gained strategic importance across India's oncology sector.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 forming the historical reference window. Mandatory market values supplied for 6 therapy categories and 7 cancer categories were treated as the primary quantitative source; percentage contributions were calculated directly from those values without altering the underlying figures. Secondary evidence from government, NCI, scientific and industry sources was used only for contextual indicators, clinical developments and competitive identification. Where regional, modality, route, mechanism, end-user or company-share data were absent, values were explicitly left unquantified rather than estimated.